Bioinformatics Analysis of TIMP1, HK2 and IGFBP7 as Potential Biomarkers and Therapeutic Targets of Paclitaxel Resistance in Breast Cancer

Bioinformatics Analysis of TIMP1, HK2 and IGFBP7 as Potential Biomarkers and Therapeutic Targets of Paclitaxel Resistance in Breast Cancer

Background: Paclitaxel is widely used as an adjuvant therapy in the treatment of breast cancer, yet its effectiveness decreases due to resistance problems. We conducted the present study to identify the potential paclitaxel resistance biomarkers and therapeutic targets in breast cancer employing bio...

Full description

Bibliographic Details
Main Authors:	Adam Hermawan, Herwandhani Putri
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2021-04-01
Series:	Middle East Journal of Cancer
Subjects:	breast cancer paclitaxel drug resistance bioinformatics biomarkers
Online Access:	https://mejc.sums.ac.ir/article_47024_ed57f4dd18cbd5ed95c820189c7be826.pdf

Similar Items

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy
by: Adam Hermawan, et al.
Published: (2022-09-01)

Targets and molecular mechanisms of a citrus flavonoid, hesperidin, against luminal breast cancer cells: an integrative bioinformatics analysis
by: Adam Hermawan, et al.
Published: (2019-01-01)

Integrative Bioinformatics Analysis Reveals Possible Target and Mechanism of Ellipticine Against Breast Cancer Stem Cells.
by: Adam Hermawan, et al.
Published: (2021-02-01)

Bioinformatics analysis and validation of genes related to paclitaxel's anti-breast cancer effect through immunogenic cell death
by: Qianmei Yang, et al.
Published: (2024-04-01)

Characterizing excision repair cross-complementing family genes as drug resistance biomarkers in breast cancer
by: Adam Hermawan, et al.
Published: (2023-08-01)

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study
by: Jiunn-Chang Lin, et al.
Published: (2020-12-01)

An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer
by: Mohammad Sultan, et al.
Published: (2021-08-01)

Identification of potential therapeutic target of naringenin in breast cancer stem cells inhibition by bioinformatics and in vitro studies
by: Adam Hermawan, et al.
Published: (2021-01-01)

Evaluate the Clinical Outcome of Nanoparticle Albumin-bound Paclitaxel on Breast Cancer Treatment: A Systematic Review and Meta-analysis
by: Yasaman Shariati, et al.
Published: (2022-09-01)

Transcriptomics analysis reveals distinct mechanism of breast cancer stem cells regulation in mammospheres from MCF-7 and T47D cells
by: Adam Hermawan, et al.
Published: (2024-01-01)

Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
by: Danbo Yang, et al.
Published: (2010-12-01)

Albumin-bound paclitaxel in the treatment of metastatic breast cancer
by: E V Artamonova
Published: (2017-01-01)

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
by: Mahtani RL, et al.
Published: (2018-02-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen
by: Adam Hermawan, et al.
Published: (2022-12-01)

Bioinformatics and In Vitro Studies Reveal the Importance of p53, PPARG and Notch Signaling Pathway in Inhibition of Breast Cancer Stem Cells by Hesperetin
by: Adam Hermawan, et al.
Published: (2021-02-01)

Identification of Key Genes and Pathways Associated With Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis
by: Zhimin Shen, et al.
Published: (2021-08-01)

Identification of TIMP1 as an inflammatory biomarker associated with temporal lobe epilepsy based on integrated bioinformatics and experimental analyses
by: Ya He, et al.
Published: (2023-06-01)

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
by: Peng Cao, et al.
Published: (2023-09-01)

Improved antitumor efficacy of paclitaxel with nano-formulation in breast cancer
by: Ding Shuang, et al.
Published: (2017-06-01)

Association of Paclitaxel Induced Neuropathy with Quality of Life of Patients with Non-Metastatic Breast Cancer
by: Masaba Masood, et al.
Published: (2023-06-01)

Two Cases of Mastectomy after Paclitaxel + Bevacizumab Therapy for Locally Advanced Breast Cancer
by: Chika Shinoda, et al.
Published: (2014-05-01)

Systemic Immune Activation, Anemia and Thrombocytosis in Breast Cancer Patients Treated by Doxorubicin and Paclitaxel
by: Melichar Bohuslav, et al.
Published: (2006-11-01)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
by: Yizhao Xie, et al.
Published: (2021-11-01)

Biomarker potential of the LEF1/TCF family members in breast cancer: Bioinformatic investigation on expression and clinical significance
by: Beatriz Miotto Lima, et al.
Published: (2023-12-01)

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
by: Miao Liu, et al.
Published: (2021-02-01)

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer
by: Laura Cabeza, et al.
Published: (2022-11-01)

miR-107 enhances the sensitivity of breast cancer cells to paclitaxel
by: Ma Changpo, et al.
Published: (2019-06-01)

Surface Modified Carvacrol-rich Satureja khuzestanica Essential Oil Nanoemulsion: A Novel Paclitaxel Formulation Induced Apoptosis on Paclitaxel-Resistant Breast Cancer Cells
by: Zeinab Mazarei, et al.
Published: (2024-01-01)

Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo
by: Wang N, et al.
Published: (2017-02-01)

Metabolic flare phenomenon mimicking disease progression on 18Flouride– Fluorodeoxyglucose PET/CT scan in breast cancer treated with paclitaxel-based chemotherapy
by: Vijay Singh, et al.
Published: (2023-06-01)

Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer
by: Vikram Gota, et al.
Published: (2021-05-01)

Urinary NGAL, IGFBP-7, and TIMP-2: novel biomarkers to predict contrast medium-induced acute kidney injury in children
by: Qianliang Sun, et al.
Published: (2022-12-01)

Therapeutic effect and mechanism of paclitaxel on diabetic retinopathy model rats
by: Dan Guo, et al.
Published: (2019-12-01)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
by: Junji Tsurutani, et al.
Published: (2021-02-01)

Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
by: A. G. Kedrova, et al.
Published: (2019-11-01)

Construction of a paclitaxel-related competitive endogenous RNA network and identification of a potential regulatory axis in pancreatic cancer
by: Si Yuan Lu, et al.
Published: (2022-06-01)

Accelerating Breast Cancer Biomarker Discovery by Mass Spectrometry Proteomics and Current Bioinformatics Tools
by: Maritess D Cation, et al.
Published: (2022-09-01)

Evaluating TIMP-2 and IGFBP-7 as a predictive tool for kidney injury in ureteropelvic junction obstruction
by: Marcos Figueiredo Mello, et al.
Published: (2022-03-01)

Urinary TIMP-2 and IGFBP7 for the prediction of acute kidney injury following cardiac surgery
by: Yimei Wang, et al.
Published: (2017-05-01)